Nisha Unni, M.D. Titles and Appointments Associate Professor School Medical School Department Internal Medicine You have reached the Academic Profile. For more information on the doctor and patient care, please visit the clinical profile. Biography Nisha Unni, M.D, is an Associate Professor of Internal Medicine at UT Southwestern Medical Center, and a member of its Division of Hematology and Oncology. She specializes in breast cancer. Dr. Unni earned her medical degree from the University of Kerala, Government Medical College, in India. After completing an internal medicine residency at Saint Vincent Hospital, a teaching affiliate of the University of Massachusetts, she performed a clinical fellowship in transfusion medicine and blood banking at the Yale University School of Medicine – Yale New Haven Hospital, followed by a clinical fellowship in hematology and oncology at the University of Medicine and Dentistry of New Jersey – Robert Wood Johnson Medical School, where she served as Chief Fellow. Board certified in internal medicine, hematology, and medical oncology, she joined the UT Southwestern faculty in 2013. She is a member of the American College of Physicians, the American Society of Clinical Oncology. Her research interests include endocrine therapy resistance in hormone receptor positive breast cancer and targeted therapies. Dr. Unni’s interests outside of medicine include spending time with her family, traveling, reading, and enjoying the great outdoors. Education Medical School Trivandrum Medical College, India (2003) Residency Saint Vincent Hospital (2009), Internal Medicine Fellowship Yale New Haven Hospital (2010), Blood Banking/transfusion Medicine Fellowship UMDNJ-Robert Wood Johnson Medical School (2013), Hematology Oncology Research Interest Clinical trials HER-2/neu positive breast cancer Hormone-receptor positive breast cancer, endocrine therapy resistance Targeted therapies in breast cancer Triple negative breast cancer Publications Featured Publications CD8+ T cells in the tumor microenvironment modulate response to endocrine therapy in breast cancer. Napolitano F, Wang Y, Sudhan DR, Gonzalez-Ericsson PI, Formisano L, Unni N, Shakeel S, Zhu JZ, Ahuja K, Guo L, Chica-Parrado MR, Matsunaga Y, Luna P, Lin CA, Uemoto Y, Lee KM, Ma H, Evans NJ, Servetto A, Mendiratta S, Barnes SD, Bianco R, Fang YV, Xu L, Lee J, Wang T, Balko JM, Mills GB, Labrie M, Hanker AB, Arteaga CL, J Clin Invest 2025 Dec Ablative Preoperative Single-Fraction Radiation Dose Escalation Among Patients With Breast Cancer: A Phase 1 Nonrandomized Clinical Trial. Rahimi A, Leitch M, Dogan B, Liu Y, Alluri P, Arbab M, Li X, Parsons DDM, Kim DWN, Wandrey N, Farr D, Seiler S, Unni N, Nguyen A, Wooldridge R, Chiu TD, Lu W, Stojadinovic S, Visak J, Nwachukwu C, Patel I, Morgan H, Bahrami S, Stein M, McArthur HL, Sahoo S, Timmerman R, JAMA Netw Open 2025 Nov 8 11 e2543689 Factors Associated With Male Breast Cancer Incidence Among Prostate Cancer Survivors: Real World Evidence From Veterans Affairs National Prostate Cancer Data Core. Whyne EZ, Choi SH, Unni N, Kanjwal S, Dowell JE, Jeon-Slaughter H, Prostate 2025 Oct Adverse events in patients treated with neoadjuvant chemo/immunotherapy for triple negative breast cancer: results from seven academic medical centers. Mezzanotte-Sharpe J, Hsu CY, Choi D, Sheffield H, Zelinskas S, Proskuriakova E, Montalvo M, Lee DS, Whisenant JG, Gaffney K, Thompson MS, Blenman K, Tawagi K, Symonds L, Santa-Maria C, Unni N, Quiroga D, Shyr Y, Kennedy LC, Breast Cancer Res Treat 2025 Aug 213 1 71-80 Phase 1/2 study of H3B-6545 in women with locally advanced/metastatic estrogen receptor-positive, HER2-negative breast cancer. Hamilton E, Pluard T, Wang JS, Morikawa A, Johnston S, Dees EC, Vaklavas C, Armstrong A, Munster P, Unni N, Wright GS, Kayali F, Song T, Rong Y, Yamaguchi K, Juric D, Breast Cancer Res 2025 Aug 27 1 151 Phase Ib Trial of Fulvestrant, Palbociclib and Erdafitinib, a pan-FGFR Tyrosine Kinase Inhibitor, in HR+/HER2- Metastatic Breast Cancer. Gonzalez-Ericsson PI, Unni N, Jhaveri K, Stringer-Reasor E, Liu Q, Wang Y, Sanchez V, Garcia G, Sanders ME, Lehmann BD, Balko JM, Park B, Rexer BN, Mayer IA, Arteaga CL, Clin Cancer Res 2025 Jul Patterns of Breast Cancer Screening and Access to Care in a Safety-Net System. Su M, Kanjwal S, Hopson M, Kashanian S, Ahn C, Syed S, Delgado-Ramos GM, Unni N, Sadeghi N, Am J Prev Med 2025 Jul 69 5 108014 A Randomized Phase 2 Study of Neratinib With or Without Fulvestrant for Patients With HER2-Positive, Estrogen Receptor-Positive Metastatic Breast Cancer. Morganti S, Chu X, Ballinger TJ, Unni N, Sinclair S, Wesolowski R, Pereslete AM, Lange P, Tayob N, Lin NU, Leone JP, Krop IE, Tolaney SM, Parsons HA, Clin Breast Cancer 2025 May ESR1 Y537S and D538G mutations drive resistance to CDK4/6 inhibitors in estrogen receptor-positive breast cancer. Lin CA, Chica-Parrado MR, Unni N, Jaeger E, Fang YV, Guo L, Napolitano F, Luna P, Harris M, Chao C, Xu L, Arteaga CL, Hanker AB, Clin Cancer Res 2025 Feb Neratinib Efficacy in Patients With EGFR Exon 18-Mutant Non-Small-Cell Lung Cancer: Findings From the SUMMIT Basket Trial. Goldman JW, Bueno AM, Dooms C, Jhaveri K, de Miguel M, Piha-Paul SA, Unni N, Zick A, Mahipal A, Suga JM, Naltet C, Antoñanzas M, Crown J, Bebchuk J, Eli LD, Lowenthal BH, Mahalingam D, Clin Lung Cancer 2024 Dec Results 1-10 of 29 1 2 3 Next Last Honors & Awards Eugene P. Frenkel, M.D. Outstanding Teacher AwardUTSW Hematology & Oncology Fellowship Program (2024) Eugene P. Frenkel, M.D. Outstanding Teacher AwardUTSW Hematology & Oncology Fellowship Program (2014) Professional Associations/Affiliations American College of Physicians (2007-2010) American Society of Hematology (2011) American Society of Oncology (2011) Hemostasis & Thrombosis Research Society (2012-2013)
